1. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.
- Author
-
Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, Kumar S, Cameron D, Sethi S, Ali-Fehmi R, Morris R, Bouwman DL, Munkarah AR, Weaver DW, Gruber SA, and Batchu RB
- Subjects
- Animals, Apoptosis, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p21 genetics, Enhancer of Zeste Homolog 2 Protein, Female, Humans, Mice, Mice, SCID, Mutation, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Transplantation, Oligonucleotide Array Sequence Analysis, Ovarian Neoplasms genetics, Polycomb Repressive Complex 2 genetics, Tumor Suppressor Protein p53 genetics, Cyclin-Dependent Kinase Inhibitor p21 metabolism, Gene Expression Regulation, Neoplastic, Ovarian Neoplasms pathology, Polycomb Repressive Complex 2 metabolism, RNA Interference, Tumor Suppressor Protein p53 metabolism
- Abstract
The enhancer of zeste homolog 2 (EZH2) methyltransferase is a transcriptional repressor. EZH2 is abnormally elevated in epithelial ovarian cancer (EOC). We demonstrated that EZH2 knockdown inhibited cell growth, activated apoptosis, and enhanced chemosensitivity. Further, silencing of EZH2 resulted in re-expression of p21(waf1/cip1) and down-regulation of mutant p53. Finally, EZH2 knockdown contributed to attenuated EOC growth in SCID mice., (Published by Elsevier Ireland Ltd.)
- Published
- 2013
- Full Text
- View/download PDF